Cargando…

Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients

Immunosuppressive drugs commonly used in the treatment of psoriatic arthritis make patients more susceptible to viral, bacterial, and fungal infections because of their mechanism of action. They not only increase the risk of new infections but also act altering the natural course of preexisting infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Laurenti, R., Giovannangeli, F., Gubinelli, E., Viviano, M. T., Errico, A., Leoni, L., Ballanti, E., Migliore, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623386/
https://www.ncbi.nlm.nih.gov/pubmed/23606869
http://dx.doi.org/10.1155/2013/410521
_version_ 1782265913729351680
author Laurenti, R.
Giovannangeli, F.
Gubinelli, E.
Viviano, M. T.
Errico, A.
Leoni, L.
Ballanti, E.
Migliore, A.
author_facet Laurenti, R.
Giovannangeli, F.
Gubinelli, E.
Viviano, M. T.
Errico, A.
Leoni, L.
Ballanti, E.
Migliore, A.
author_sort Laurenti, R.
collection PubMed
description Immunosuppressive drugs commonly used in the treatment of psoriatic arthritis make patients more susceptible to viral, bacterial, and fungal infections because of their mechanism of action. They not only increase the risk of new infections but also act altering the natural course of preexisting infections. While numerous data regarding the reactivation of tuberculosis infection are available in the literature, poor information about the risk of reactivation or exacerbation of hepatitis viruses B and C infections during treatment with biologics has been reported. Furthermore, reported series with biological therapy included short periods of followup, and therefore, they are not adequate to verify the risk of reactivation in the long-term treatment. Our study evaluated patients with a history of hepatitis B and psoriatic arthritis treated with adalimumab and monitored up to six years. During the observation period, treatment was effective and well tolerated in all patients, and liver function tests and viral load levels remained unchanged.
format Online
Article
Text
id pubmed-3623386
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36233862013-04-19 Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients Laurenti, R. Giovannangeli, F. Gubinelli, E. Viviano, M. T. Errico, A. Leoni, L. Ballanti, E. Migliore, A. Clin Dev Immunol Clinical Study Immunosuppressive drugs commonly used in the treatment of psoriatic arthritis make patients more susceptible to viral, bacterial, and fungal infections because of their mechanism of action. They not only increase the risk of new infections but also act altering the natural course of preexisting infections. While numerous data regarding the reactivation of tuberculosis infection are available in the literature, poor information about the risk of reactivation or exacerbation of hepatitis viruses B and C infections during treatment with biologics has been reported. Furthermore, reported series with biological therapy included short periods of followup, and therefore, they are not adequate to verify the risk of reactivation in the long-term treatment. Our study evaluated patients with a history of hepatitis B and psoriatic arthritis treated with adalimumab and monitored up to six years. During the observation period, treatment was effective and well tolerated in all patients, and liver function tests and viral load levels remained unchanged. Hindawi Publishing Corporation 2013 2013-03-27 /pmc/articles/PMC3623386/ /pubmed/23606869 http://dx.doi.org/10.1155/2013/410521 Text en Copyright © 2013 R. Laurenti et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Laurenti, R.
Giovannangeli, F.
Gubinelli, E.
Viviano, M. T.
Errico, A.
Leoni, L.
Ballanti, E.
Migliore, A.
Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients
title Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients
title_full Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients
title_fullStr Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients
title_full_unstemmed Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients
title_short Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients
title_sort long-term safety of anti-tnf adalimumab in hbc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623386/
https://www.ncbi.nlm.nih.gov/pubmed/23606869
http://dx.doi.org/10.1155/2013/410521
work_keys_str_mv AT laurentir longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients
AT giovannangelif longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients
AT gubinellie longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients
AT vivianomt longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients
AT erricoa longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients
AT leonil longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients
AT ballantie longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients
AT migliorea longtermsafetyofantitnfadalimumabinhbcantibodypositivepsoriaticarthritispatientsaretrospectivecaseseriesof8patients